Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes
The Strong Heart Study
Jennifer E. Liu, MD, FACC ,*,
David C. Robbins, MD ,
Vittorio Palmieri, MD*,
Jonathan N. Bella, MD, FACC*,
Mary J. Roman, MD, FACC*,
Richard Fabsitz, MA ,
Barbara V. Howard, PhD ,
Thomas K. Welty, MD, MPH||,
Elisa T. Lee, PhD¶ and
Richard B. Devereux, MD, FACC*
* Department of Medicine, the New York Hospital-Cornell Medical Center, New York, New York, USA
Division of Cardiology, the New York Hospital-Cornell Medical Center, New York, New York, USA
National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
Medstar Research Institute, Washington, DC, USA
|| Aberdeen Area Tribal Chairmens Health Board, Rapid City, South Dakota, USA
¶ School of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

View larger version (19K):
[in a new window]
|
Figure 1 Prevalence of subnormal midwall shortening (MWS) based on albuminuria status, where I = no albuminuria; II = microalbuminuria; and III = macroalbuminuria. Solid bars = percentage of subnormal MWS. Comparison between each group was made using chi-squared statistics with Bonferroni correction.
|
|

View larger version (22K):
[in a new window]
|
Figure 2 Prevalence of abnormal diastolic function based on albuminuria status where I = no albuminuria; II = microalbuminuria; and III = macroalbuminuria. Solid bars = percentage of abnormal diastolic function. Comparison between each group was made using chi-squared statistics with Bonferroni correction.
|
|
|